Lexicon Pharmaceuticals announced that it will present three sets of clinical data at the American College of Cardiology (ACC) Annual Scientific Session & Expo in New Orleans, Louisiana, scheduled for March 28‑30, 2026.
The presentations will cover data from the Phase 3 SCORED study of sotagliflozin in patients with type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors, as well as two analyses from the SOTA‑P‑CARDIA trial in patients with heart‑failure with preserved ejection fraction (HFpEF). These are the first public disclosures of these late‑stage trial results, providing clinicians and regulators with new evidence on the drug’s efficacy and safety across a broad patient population.
The SCORED data suggest that sotagliflozin can reduce heart‑failure events and major adverse cardiovascular events regardless of body‑mass index, while the SOTA‑P‑CARDIA analyses indicate improvements in quality of life and physical limitations for HFpEF patients without diabetes. The findings could support future regulatory submissions and broaden the drug’s therapeutic indications, potentially expanding its market reach.
Lexicon’s Q4 2025 financial results, released on March 5, 2026, showed a net loss of $15.5 million ($0.04 per share) versus a $33.8 million loss ($0.09 per share) in the same period a year earlier, and revenue of $5.5 million against a $3.92 million estimate. The improved earnings beat was driven by significant reductions in selling, general, and administrative expenses and research and development costs, reflecting a strategic shift that has strengthened the company’s cash position, which stood at $125.2 million as of December 31, 2025, and was further bolstered by over $100 million in new cash raised in February 2026.
Beyond sotagliflozin, Lexicon is advancing other candidates, including LX9211 for diabetic peripheral neuropathic pain and LX9851 for obesity, underscoring a diversified pipeline that supports long‑term growth prospects.
"These data build upon the already strong body of evidence supporting the benefits of SGLT1 and SGLT2 inhibition in reducing heart failure and MACE events, as well as provide meaningful insights into the application of sotagliflozin across a broad and diverse patient population," said Dr. Craig Granowitz, Chief Medical Officer of Lexicon Pharmaceuticals.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.